Press Release

IQVIA and three leading university medical centers launch the first Prime Site in the Netherlands to advance clinical and real-world research

Sep 11, 2023

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry and healthcare stakeholders, announced a collaboration with three university medical centers in the Netherlands - University Medical Center Utrecht (UMC Utrecht), Maastricht University Medical Center+ (MUMC+) and Radboud university medical center (Radboudumc) – and has launched the first Prime Site in the country to advance clinical research through data and innovation.

The combined expertise of the university medical centers and the capabilities of IQVIA will advance innovation and data-driven research and care, resulting in research program optimization, clinical trial start time reduction and better alignment on procedures. By leveraging IQVIA’s in-depth healthcare knowledge combined with innovative technology platforms, the medical centers will gain insights from analytics applied to real-world and clinical trial data to support a significant increase in complex clinical trials and real-world studies.

With this strategic collaboration, the Netherlands becomes the 12th country in Europe with an IQVIA Prime Site, joining a growing network which creates unique opportunities to move research forward and make further significant steps towards more equitable access to effective healthcare.

This collaboration has brought together three leading university medical centers in the Netherlands, out of a total of seven academic hospitals in the country, with other potential partners to join at a later stage.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About UMC Utrecht, MUMC+ and Radboudumc

UMC Utrecht is a leading international university medical center generating, testing, sharing, and applying knowledge on health, illness, and health care for the benefit of patients and society. Since everyone deserves the best possible healthcare, UMC Utrecht always sets the bar high. The result: innovative, cutting-edge medical treatment that meets the healthcare needs of today and the future. We develop our unique knowledge in this respect together with patients, patient organizations and several partners. Our doctors, researchers and students join forces to solve major medical issues. Patients at UMC Utrecht receive treatment specifically geared to their specific individual needs. Everything we do is aimed at making and keeping people healthy – and at preventing sickness too.

MUMC+ is a partnership between Maastricht University Hospital and Maastricht University's Faculty of Health, Medicine and Life Sciences. MUMC+ is nationally and internationally renowned for not only focusing on curing patients and restoring people’s health, but also on prevention and health promotion to support people in staying healthy and improve their health and quality of life. In addition to tertiary referral care and top-level clinical patient care, its core tasks are scientific research, academic education and training, and valorisation. Clinical Trial Center Maastricht (CTCM) is a subsidiary company of Maastricht University Hospital, serving as trial office and starting point for each research project involving human subjects within MUMC+.

Radboudumc specializes in patient care, scientific research, teaching and training. Radboudumc has the ambition to lead the way in shaping the health and healthcare of the future. Its mission is 'to have a significant impact on health and healthcare', realized in an innovative and person-centered way. Radboudumc focusses on prevention, sustainability, meaningful care, data-driven & artificial intelligence, biomedical diagnostics & therapies and training the professionals of tomorrow.

Contact Us